ondansetron has been researched along with Dizziness in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with ondansetron alone, the casopitant and ondansetron combination results in superior emesis prevention during the first 24 h postoperatively in female patients with known risk factors for postoperative nausea and vomiting." | 5.14 | Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. ( Blackburn, L; Chung, F; Johnson, B; Kutsogiannis, DJ; Lane, SR; Levin, J; Pergolizzi, JV; Singla, NK; Singla, SK, 2010) |
| "However, postoperative nausea and vomiting was significantly lower in groups II and III (p < 0." | 2.73 | Postoperative intravenous patient-controlled analgesia in thyroid surgery: comparison of fentanyl and ondansetron regimens with and without the nonsteriodal anti-inflammatory drug ketorolac. ( Chang, DJ; Kim, EM; Kim, KJ; Kim, SY; Nam, KH; Nam, SH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, SY | 1 |
| Kim, EM | 1 |
| Nam, KH | 1 |
| Chang, DJ | 1 |
| Nam, SH | 1 |
| Kim, KJ | 1 |
| Singla, NK | 1 |
| Singla, SK | 1 |
| Chung, F | 1 |
| Kutsogiannis, DJ | 1 |
| Blackburn, L | 1 |
| Lane, SR | 1 |
| Levin, J | 1 |
| Johnson, B | 1 |
| Pergolizzi, JV | 1 |
| Shuster, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered With Intravenous Ondan[NCT00108095] | Phase 2 | 701 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ondansetron and Dizziness
| Article | Year |
|---|---|
Postoperative intravenous patient-controlled analgesia in thyroid surgery: comparison of fentanyl and ondansetron regimens with and without the nonsteriodal anti-inflammatory drug ketorolac.
Topics: Adult; Analgesia, Patient-Controlled; Anti-Inflammatory Agents, Non-Steroidal; Dizziness; Female; Fe | 2008 |
Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients.
Topics: Administration, Oral; Adolescent; Adult; Anesthesia, General; Antiemetics; Cholecystectomy, Laparosc | 2010 |
1 other study available for ondansetron and Dizziness
| Article | Year |
|---|---|
Ondansetron and headache.
Topics: Antiemetics; Dizziness; Female; Fever; Headache; Humans; Middle Aged; Nursing Assessment; Ondansetro | 1999 |